Abstract: A pharmaceutical composition for prevention or treatment of a disease or disorder characterized by chronic inflammation, associated with angiogenesis and fibrosis. The pharmaceutical composition includes a multi-target inhibitor, multi-phase modulator, or multi-kinase inhibitor, such as axitinib, nintedanib, pirfenidone, riociguat, sorafenib, sunitinib, lenvatinib, regorafenib, ponatinib, or pazopanib.

Abstract: A method for preventing and/or treating fibrosis associated with an eye-related disease or disorder includes administering an effective amount of a multikinase inhibitor to a subject in need thereof. The multikinase inhibitor is nintedanib, lenvatinib, a combination thereof, or a salt thereof. The eye-related disease or disorder is corneal transparency, corneal scar formation, secondary cataract formation, glaucoma filtration surgery, ocular surgical procedures and implants, photorefractive keratectomy, laser in situ keratomileusis, formation and contraction of pre- and epiretinal membranes, proliferative vitreoretinopathy, subretinal fibrosis/scarring, retinal gliosis, or formation of choroidal membranes.

Abstract: This disclosure relates to a pharmaceutical bio-dissolvable/bioerodible aqueous gel system optionally comprising an active pharmaceutical ingredient, wherein the pharmaceutical composition makes a transition from liquid to gel near the body temperature of a mammal These compositions may include a reversibly-gelling material, such as methylcellulose and a rheology modifier such as citrate.

Abstract: A pharmaceutical composition for prevention or treatment of a disease or disorder characterized by chronic inflammation, associated with angiogenesis and fibrosis. The pharmaceutical composition includes a multi-target inhibitor, multi-phase modulator, or multi-kinase inhibitor, such as axitinib, nintedanib, pirfenidone, riociguat, sorafenib, sunitinib, lenvatinib, regorafenib, ponatinib, or pazopanib.

Abstract: A pharmaceutical composition for prevention or treatment of a disease or disorder characterized by chronic inflammation, with associated angiogenesis and fibrosis, wherein the disease or disorder is selected from the group consisting of rosacea, psoriasis, erythema multiforme, bullous pemphigoid, hereditary hemorrhagic telangiectasia, rheumatoid arthritis, atopic dermatitis, and dermal wound healing. The pharmaceutical composition includes at least one multi-kinase inhibitor selected from the group consisting of axitinib, nintedanib, and lenvatinib.

Abstract: This disclosure relates to aqueous suspension formulations of multi-target inhibitors. These formulations can be locally administered to target tissues such as eyes, prostate, that may be solved by the present disclosure are to (1) provide an injectable dosage form that allows direct delivery of a multi-target inhibitor to the proximity of the diseased tissue, (2) be compatible with the tissue of the site of administration, (3) form a drug reservoir at the administration site to allow prolonged supply of the drug to the diseased tissue, and thus reduce dosing frequency, (4) the release rate of the drug from the reservoir is such that above therapeutic level of the drug in the diseased tissue is achievable, (5) have physicochemical properties that are suitable for clinical uses, (6) be terminally sterilizable so that safety risk due to contamination of micro-organisms can be minimized, and (7) have a stability profile suitable for long term storage and distribution.

Abstract: A method for preventing and/or modulating formation of a dermal fibrotic disorder includes administering a therapeutically effective amount of a multi-phase modulator to a subject in need thereof. The multi-phase modulator is selected from the group consisting of axitinib, nintedanib, sorafenib, sunitinib, lenvatinib, panatinib, pazopanib, regorafenib, and riociguat.

Abstract: A method for preventing and/or modulating formation of a dermal fibrotic disorder includes administering a therapeutically effective amount of a multi-phase modulator to a subject in need thereof. The multi-phase modulator is selected from the group consisting of axitinib, nintedanib, sorafenib, sunitinib, lenvatinib, panatinib, pazopanib, regorafenib, and riociguat. The dermal fibrotic disorder is acne scars, skin scars such as keloids and hypertrophic scars, wrinkles, cellulite and dermal neoplastic fibrosis, scarring alopecia, various vasculopathy, vasculitis, burn wound healing, diabetic foot syndrome, scleroderma, arthrofibrosis, peyronie's disease, dupuytren's contracture, or adhesive capsulitis.

Abstract: A system of content/query feature based data structure retrieval of predicted values is provided. The system can create a data structure having a plurality of rows corresponding to individual content/query features and a plurality of columns corresponding to individual predicted values. The processors can obtain a set of session features associated with a selection by a computing device in response to a query, and a set of content/query features associated with the selection of the content item. The processors can retrieve, from the data structure, a set of predicted values for each of the set of content/query features. The processors can generate, for each of the set of content/query features, a set of aggregate predicted values for each of the set of content/query features, and can include the set of aggregate predicted values in the data structure.

Abstract: A pharmaceutical composition for prevention or treatment of a disease or disorder characterized by chronic inflammation, with associated angiogenesis and fibrosis, wherein the disease or disorder is selected from the group consisting of rosacea, psoriasis, erythema multiforme, bullous pemphigoid, hereditary hemorrhagic telangiectasia, rheumatoid arthritis, atopic dermatitis, and dermal wound healing. The pharmaceutical composition includes at least one multi-kinase inhibitor selected from the group consisting of axitinib, nintedanib, and lenvatinib.

Abstract: A method for preventing and/or treating fibrosis associated with an eye-related disease or disorder includes administering an effective amount of a multikinase inhibitor to a subject in need thereof. The multikinase inhibitor is nintedanib, lenvatinib, a combination thereof, or a salt thereof. The eye-related disease or disorder is corneal transparency, corneal scar formation, secondary cataract formation, glaucoma filtration surgery, ocular surgical procedures and implants, photorefractive keratectomy, laser in situ keratomileusis, formation and contraction of pre- and epiretinal membranes, proliferative vitreoretinopathy, subretinal fibrosis/scarring, retinal gliosis, or formation of choroidal membranes.

Abstract: A method for preventing and/or modulating formation of a dermal fibrotic disorder includes administering a therapeutically effective amount of a multi-phase modulator to a subject in need thereof. The multi-phase modulator is selected from the group consisting of axitinib, nintedanib, sorafenib, sunitinib, lenvatinib, panatinib, pazopanib, regorafenib, and riociguat.

Abstract: In one aspect, an example method involves selecting, by a computing device, a message to be output to a user; determining a classification group to which the user belongs; using the determined classification group to which the user belongs as a basis to select a device from among a plurality of devices associated with the user; and transmitting, by the computing device, an instruction via a communication network, wherein the instruction is configured to cause the selected device to output the selected message.

Abstract: Methods and systems for improving a presentation function of a client device based on feedback data indicative of presentation effectiveness are disclosed. A server transmits, over a communication network, a first instruction that configures the client device to provide a first presentation via a user interface to an individual. The server receives physiological data collected by one or more sensors of the client device and associated with the individual and the first presentation. Based on feedback data, including the received physiological data, representative of behavior change subject to the first presentation, the server computes an effectiveness assessment of the first presentation.

Abstract: A system of content/query feature based data structure retrieval of predicted values is provided. The system can create a data structure having a plurality of rows corresponding to individual content/query features and a plurality of columns corresponding to individual predicted values. The processors can obtain a set of session features associated with a selection by a computing device in response to a query, and a set of content/query features associated with the selection of the content item. The processors can retrieve, from the data structure, a set of predicted values for each of the set of content/query features. The processors can generate, for each of the set of content/query features, a set of aggregate predicted values for each of the set of content/query features, and can include the set of aggregate predicted values in the data structure.

Abstract: Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.

Abstract: A system obtains a first parameter (QP1) associated with a quality of an advertisement among multiple advertisements, where the first quality parameter (QP1) does not include a click through rate (CTR). The system functionally combines the first quality parameter (QP1) with at least one other parameter and uses the functional combination to filter, rank or promote the advertisement among the multiple advertisements.

Abstract: A system obtains ratings associated with a first set of advertisements hosted by one or more servers, where the ratings indicate a quality of the first set of advertisements. The system observes multiple different first user actions associated with user selection of advertisements of the first set of advertisements and derives a statistical model using the observed first user actions and the obtained ratings. The system further observes second user actions associated with user selection of a second advertisement hosted by the one or more servers and uses the statistical model and the second user actions to estimate a quality of the second advertisement.

Abstract: A system obtains a first parameter (QP1) associated with a quality of an advertisement among multiple advertisements, where the first quality parameter (QP1) does not include a click through rate (CTR). The system functionally combines the first quality parameter (QP1) with at least one other parameter and uses the functional combination to filter, rank or promote the advertisement among the multiple advertisements.

Abstract: A system obtains a first parameter (QP1) associated with a quality of an advertisement among multiple advertisements, where the first quality parameter (QP1) does not include a click through rate (CTR). The system functionally combines the first quality parameter (QP1) with at least one other parameter and uses the functional combination to filter, rank or promote the advertisement among the multiple advertisements.